Tetraspecific ligand for tumor-targeted delivery of nanomaterials

Biomaterials

Volumn 35, Issue 23, 2014, Pages 6026-6036

  Kim, Dongwook ^a,b   Friedman, Adam D ^a,b   Liu, Rihe ^a,b  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Hyperthermia cancer therapy; Multispecificity; Synergistic binding; Targeted nanomaterials; Targeting ligand; Tetraspecific

Indexed keywords

CELL CULTURE; CELLS; DISEASES; ESCHERICHIA COLI; NANOSTRUCTURED MATERIALS; ONCOLOGY; PROTEINS; SURFACE PLASMON RESONANCE; TUMORS;

HYPERTHERMIA CANCER THERAPIES; MULTISPECIFICITY; SYNERGISTIC BINDING; TARGETING LIGANDS; TETRASPECIFIC;

LIGANDS;

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GOLD NANOPARTICLE; HYBRID PROTEIN; NANOMATERIAL; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR; GOLD; METAL NANOPARTICLE; NANOCOMPOSITE; TUMOR PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; CANCER CELL LINE; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; HYPERTHERMIC THERAPY; INTERFEROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE PLASMON RESONANCE; CHEMISTRY; HUMAN; INDUCED HYPOTHERMIA; K562 CELL LINE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

GOLD; HUMANS; HYPOTHERMIA, INDUCED; K562 CELLS; METAL NANOPARTICLES; MOLECULAR TARGETED THERAPY; NANOCOMPOSITES; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; TREATMENT OUTCOME;

EID: 84900022316     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.015     Document Type: Article

References (45)

1. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-781.
2. Vigderman L., Zubarev E.R. Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules. Adv Drug Deliv Rev 2013, 65:663-676.
3. Friedman A.D., Claypool S.E., Liu R. The smart targeting of nanoparticle. Curr Pharm Des 2013, 19:6315-6329.
4. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
5. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., Roman L., Pedrini J.L., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. NEngl J Med 2012, 366:109-119.
6. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
7. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Kinzler K.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analysis. Science 2008, 321:1801-1806.
8. Dong J., Sereno A., Aivazian D., Langley E., Miller B.R., Snyder W.B., et al. Astable IgG like bispecific antibody targeting the epidemal growth factor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011, 3:273-288.
9. Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323:1610-1614.
10. Sliwkowski M.X., Mellman I. Antibody therapeutics in cancer. Science 2013, 341:1192-1198.
11. Kontermann R.E. Dual targeting strategies with bispecific antibodies. MAbs 2012, 4:182-197.
12. LaFleur D.W., Abramyan D.A., Kanakara P., Smith R.G., Shah R.R., Wang G., et al. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. MAbs 2013, 5(2):208-218.
13. Gossage L., Eisen T. Targeting multiple kinase pathways: a change in paradigm. Clin Cancer Res 2010, 16(7):1973-1978.
14. Tebbutt N., Pedersen M.W., Johns T.G. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 2013, 13:663-673.
15. Youssoufian H., Hicklin D.J., Rowinsky E.K. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 2007, 13:5544-5548.
16. Curzio R., Gian C.A. Vascular integrins: therapeutic and imaging targets of tumor angiogenesis. Angiogenes Inhib 2010, 83-101.
17. Kim D., Yan Y., Valencia C.A., Liu R. Heptameric targeting ligands against EGFR and HER2 with high stability and avidity. PLoS One 2012, 7:e43077.
18. Kruser T.J., Wheeler D.L. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010, 316:1083-1100.
19. Geuna E., Milani A., Redana S., Rossi V., Valabrega G., Aglietta M., et al. Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. Expert Opin Pharmacother 2011, 12(4):549-565.
20. Tsutsui S., Ohnom S., Murakami S., Kataoka A., Kinoshita J., Hachitanda Y. Prognostic value of the combination of epidermal growth factor and c-erB-2 in breast cancer. Surgery 2003, 133:219-221.
21. Hirsch F.R., Varella-Garcia M., Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009, 28:S32-S37.
22. Robinson S.D., Hodivala-Dilke K.M. The role of β3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol 2011, 23:630-637.
23. Somanath P.R., Malinin N.L., Brzova T.V. Cooperation between integrin αVβ3 and VEGFR2 in angiogenesis. Angiogenesis 2009, 12:177-185.
24. Ivaska J., Heino J. Interplay between cell adhesion and growth factor receptors: from the plasma membrane to the endosomes. Cell Tissue Res 2010, 339:111-120.
25. Poindessous V., Ouaret D., El Ouadriani K., Battistella A., Megalophonos V.F., Kamsu-Kon N., Petitprez A., Escargueli A.E., et al. EGFR- and VEGFR-targeted small molecule show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res 2011, 17(20):6522-6530.
26. Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel 2011, 24:3-9.
27. Nord K., Gunneriusson E., Ringdahl J., Stahl S., Uhlen M., Nygren P.A. Binding proteins selected from combinational libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997, 772-777.
28. Getmanova E.V., Chen Y., Bloom L., Gokemeijer J., Shamah S., Warikoo V., et al. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution invitro. Chem Biol 2006, 13:549-556.
29. Duan J., Wu J., Valencia C.A., Liu R. Fibronectin type III domain based monobody with high avidity. Biochemistry 2007, 12656-12664.
30. Friedman M., Orlova A., Johansson E., Eriksson T.L., Holden-Guthenberg I., Tolmachev V., et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor binding affibody molecule. JMol Biol 2008, 376:1388-1402.
31. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Holden-Guthenberg I., et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006, 66:4339-4348.
32. Chen X., Zaro J.L., Shen W.C. Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev 2013, 65:1357-1369.
33. Citartan M., Gopinath S.C.B., Tominaga J., Tang T.H. Label-free methods of reporting biomolecular interactions by optical biosensors. Analyst 2013, 138:3576-3592.
34. Smith M.C., Scaglione K.M., Assimon V.A., Patury S., Thompson A.D., Dickey C.A., Southworth D.R., Paulson H.L., et al. The E3 ubiquitin ligase CHIP and the molecular chaperone Hsc70 form a dynamic, tethered complex. Biochemistry 2013, 52(32):5354-5364.
35. Hotz B., Backer M.V., Backer J.M., Buhr H.J., Hotz H.G. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer. Neoplasia 2010, 12:797-806.
36. Huff T.B., Tong L., Zhao Y., Hansen M.N., Cheng J.X., Wei A. Hyperthermic effects of gold nanorods on tumor cells. Nanomedicine (Lond) 2007, 2:125-132.
37. Huang X., El-Sayed I.H., Qian W., El-Sayed M.A. Cancer cell imaging and hotothermal therapy in the near-infrared region by using gold nanorods. JAm Chem Soc 2006, 2115-2120.
38. West J.L., Halas N.J. Engineered nanomaterials for biophotonics applications: improving sensing, imaging, and therapeutics. Annu Rev Biomed Eng 2003, 285-292.
39. Kennedy L.C., Bickford L.R., Lewinski N.A., Coughlin A.J., Hu Y., Day E.S., et al. Anew era for cancer treatment: gold-nanoparticle-mediated thermal therapies. Small 2011, 169-183.
40. Huang Y.F., Liu H., Xiong X., Chen Y., Tan W. Nanoparticle mediated IgE receptor aggregation and signaling in RBL mast cells. JAm Chem Soc 2009, 17328-17334.
41. Day E.S., Bickford L.R., Slater J.H., Riggall N.S., Drezek R.A., West J.L. Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer. Int J Nanomed 2010, 5:445-454.
42. 18F-FRGD2. JNucl Med 2006, 47:113-121.
43. Rusnak D.W., Alligood K.J., Mullin R.J., Spehar G.M., Arenas-Elliott C., Gilmer T.M., et al. Assessment of epidermal growth factor receptor (EGFR, Erb1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 2007, 40:580-594.
44. Almeida J.P.M., Figueroa E.R., Drezek R.A. Gold nanoparticle mediated cancer immunotherapy. Nanomedicine 2013 Oct 5, pii: S1549-9634(13)00545-5. [Epub ahead of print]. 10.1016/j.nano.2013.09.011.
45. Ekerljung L., Wållberg H., Sohrabian A., Andersson K., Friedman M., Frejd F.Y., et al. Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2. Bioconjug Chem 2012, 23:1802-1811.